It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...
Ottawa, Jan. 29, 2026 (GLOBE NEWSWIRE) -- The global cell and gene therapy manufacturing market size was calculated at USD 21.15 billion in 2025 and is expected to reach around USD 215.18 billion by ...
Innovative solutions are making personalized cell and gene therapies accessible to all. Over the past two decades, 32 cell and gene therapies (CGTs) have been approved by the regulatory authorities ...
Emily Whitehead made the history books in 2012 when she become the first pediatric patient with B-cell acute lymphoblastic leukemia to be given a chimeric antigen receptor (CAR) T-cell therapy. After ...
Automation and quality control (QC) are critical in manufacturing safe and effective cell and gene therapy products. However, current QC methods, reliant on molecular staining, pose difficulty in ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
As the U.S. solar PV sector scales up domestic cell manufacturing, long-term competitiveness will depend on whether American ...
A roundtable discussion reveals how hybrid distributed models could provide a bridge from centralized cell-therapy ...
https://www.thehindubusinessline.com/companies/ola-may-incur-2200-crore-capex-in-fy25-for-cell-manufacturing-expansion/article68988345.ece Copy Ola Cell Technologies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results